HRD
About
Biomarker Type: Homologous Recombination
Present: True
Status: Deficient
Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings
Therapeutic response
Precision oncology relationships for therapeutic response involving this biomarker.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | HRD | Ovarian Epithelial Tumor | Bevacizumab, Olaparib | |
| Sensitivity (+) | HRD | High-Grade Serous Fallopian Tube Cancer | Bevacizumab, Olaparib | |
| Sensitivity (+) | HRD | Peritoneal Serous Carcinoma | Bevacizumab, Olaparib | |
| Sensitivity (+) | HRD | Ovarian Epithelial Tumor | Bevacizumab, Olaparib | |
| Sensitivity (+) | HRD | High-Grade Serous Fallopian Tube Cancer | Bevacizumab, Olaparib | |
| Sensitivity (+) | HRD | Peritoneal Serous Carcinoma | Bevacizumab, Olaparib | |
| Sensitivity (+) | HRD | Ovarian Epithelial Tumor | Bevacizumab, Olaparib | |
| Sensitivity (+) | HRD | High-Grade Serous Fallopian Tube Cancer | Bevacizumab, Olaparib | |
| Sensitivity (+) | HRD | Peritoneal Serous Carcinoma | Bevacizumab, Olaparib |